Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction
Authors: Biccirè Flavio G. , Kakizaki Ryota , Koskinas Konstantinos C. , Ueki Yasushi , Häner Jonas , Shibutani Hiroki , Lønborg Jacob , Spitzer Ernest , Iglesias Juan F. , Otsuka Tatsuhiko , Siontis George C. M. , Stortecky Stefan , Kaiser Christoph , Ambühl Maria , Morf Laura , Ondracek Anna S. , van Geuns Robert-Jan , Spirk David , Daemen Joost , Mach François , Windecker Stephan , Engstrøm Thomas , Lang Irene , Losdat Sylvain , Räber Lorenz 
Published: September 2024

ImportancePrevious studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach).ObjectiveTo investigate the effects of lipid-lowering therapy on coronary lesions with advanced atherosclerotic plaque features and presumably higher risk for future events.Design, Setting, and ParticipantsThe PACMAN-AMI randomized clinical trial (enrollment: May 2017 to October 2020; final follow-up: October 2021) randomized patients with acute myocardial infarction to receive alirocumab or placebo in addition to high-intensity statin therapy. In this post hoc lesion-level analysis, nonculprit lesions were identified as segments with plaque burden 40% or greater defined by intravascular ultrasound (IVUS). IVUS, near-infrared spectroscopy, and optical coherence tomography images at baseline and the 52-week follow-up were manually matched by readers blinded to treatment allocation. Data for this study were analyzed from October 2022 to November 2023.InterventionsAlirocumab or placebo in addition to high-intensity statin therapy.Main Outcomes and MeasuresLesion-level imaging outcome measures, including high-risk plaque characteristics and phenotypes.ResultsOf the 245 patients in whom lesions were found, 118 were in the alirocumab group (mean [SD] age, 58.2 [10.0] years; 101 [85.6%] male and 17 [14.4%] female) and 127 in the placebo group (mean [SD] age, 57.7 [8.8] years; 104 [81.9%] male and 23 [18.1%] female). Overall, 591 lesions were included: 287 lesions (118 patients, 214 vessels) in the alirocumab group and 304 lesions (127 patients, 239 vessels) in the placebo group. Lesion-level mean change in percent atheroma volume (PAV) was −4.86% with alirocumab vs −2.78% with placebo (difference, −2.02; 95% CI, −3.00 to −1.05; P &amp;lt; .001). At the minimum lumen area (MLA) site, mean change in PAV was −10.14% with alirocumab vs −6.70% with placebo (difference, −3.36; 95% CI, −4.98 to −1.75; P &amp;lt; .001). MLA increased by 0.15 mm2 with alirocumab and decreased by 0.07 mm2 with placebo (difference, 0.21; 95% CI, 0.01 to 0.41; P = .04). Among 122 lipid-rich lesions, 34 of 55 (61.8%) in the alirocumab arm and 27 of 67 (41.8%) in the placebo arm showed a less lipid-rich plaque phenotype at follow-up (P = .03). Among 63 lesions with thin-cap fibroatheroma at baseline, 8 of 26 (30.8%) in the alirocumab arm and 3 of 37 (8.1%) in the placebo arm showed a fibrous/fibrocalcific plaque phenotype at follow-up (P = .02).Conclusions and RelevanceAt the lesion level, very intensive lipid-lowering therapy induced substantially greater PAV regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion MLA and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes.Trial RegistrationClinicalTrials.gov Identifier: NCT03067844